Effect of lifestyle modification on hepatocellular carcinoma incidence and mortality among patients with chronic hepatitis B
- PMID: 37426323
- PMCID: PMC10324530
- DOI: 10.3748/wjg.v29.i24.3843
Effect of lifestyle modification on hepatocellular carcinoma incidence and mortality among patients with chronic hepatitis B
Abstract
Background: Research exploring the influence of healthier lifestyle modification (LSM) on the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) is limited.
Aim: To emulate a target trial to determine the effect of LSM on HCC incidence and mortality among patients with CHB by large-scale population-based observational data.
Methods: Among the patients with CHB enrolled in the Korean National Health Insurance Service between January 1, 2009, and December 31, 2017, those aged ≥ 20 years who drank alcohol, smoked cigarettes, and were sedentary were analyzed. Exposure included at least one LSM, including alcohol abstinence, smoking cessation, and regular exercise. The primary outcome was HCC development, and the secondary outcome was liver-related mortality. We used 2:1 propensity score matching to account for covariates.
Results: With 48766 patients in the LSM group and 103560 in the control group, the adjusted hazard ratio (HR) for incident HCC and liver-related mortality was 0.92 [95% confidence interval (CI): 0.87-0.96] and 0.92 (95%CI: 0.86-0.99) in the LSM group, respectively, compared with the control group. Among the LSM group, the adjusted HR (95%CI) for incident HCC was 0.84 (0.76-0.94), 0.87 (0.81-0.94), and 1.08 (1.00-1.16) for alcohol abstinence, smoking cessation, and regular exercise, respectively. The adjusted HR (95%CI) for liver-related mortality was 0.92 (0.80-1.06), 0.81 (0.72-0.91), and 1.15 (1.04-1.27) for alcohol abstinence, smoking cessation, and regular exercise, respectively.
Conclusion: LSM lowered the risk of HCC and mortality in patients with CHB. Thus, active LSM, particularly alcohol abstinence and smoking cessation, should be encouraged in patients with CHB.
Keywords: Cancer; Chronic hepatitis B; Hepatocellular carcinoma; Lifestyle modification; Mortality.
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: All authors have nothing to disclose.
Figures
Similar articles
-
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.J Hepatol. 2020 Jun;72(6):1088-1096. doi: 10.1016/j.jhep.2020.01.007. Epub 2020 Jan 22. J Hepatol. 2020. PMID: 31981727
-
Statin use and the risk of hepatocellular carcinoma among patients with chronic hepatitis B: an emulated target trial using longitudinal nationwide population cohort data.BMC Gastroenterol. 2023 Oct 25;23(1):366. doi: 10.1186/s12876-023-02996-w. BMC Gastroenterol. 2023. PMID: 37880589 Free PMC article. Clinical Trial.
-
Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma.Aliment Pharmacol Ther. 2019 Jun;49(12):1509-1517. doi: 10.1111/apt.15269. Epub 2019 Apr 25. Aliment Pharmacol Ther. 2019. PMID: 31025388
-
Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.Hepatology. 2021 Jan;73(1):68-78. doi: 10.1002/hep.31267. Epub 2020 Nov 6. Hepatology. 2021. PMID: 32277491 Free PMC article.
-
Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.J Gastroenterol Hepatol. 2022 May;37(5):782-794. doi: 10.1111/jgh.15783. Epub 2022 Feb 7. J Gastroenterol Hepatol. 2022. PMID: 35080052 Review.
Cited by
-
Epidemiology, natural history, and management of patients with CHB concurrent with MASLD.Clin Liver Dis (Hoboken). 2024 Jun 19;23(1):e0171. doi: 10.1097/CLD.0000000000000171. eCollection 2024 Jan-Jun. Clin Liver Dis (Hoboken). 2024. PMID: 38903875 Free PMC article. Review. No abstract available.
References
-
- Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018;142:2471–2477. - PubMed
-
- Jachs M, Tillmann HL. It's not all about the virus-On the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B. Hepatology. 2023;77:352–354. - PubMed
-
- Wu S, Zhou J, Wu X, Sun Y, Wang B, Kong Y, Zhan S, Jia J, Yang HI, You H. Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints. Am J Gastroenterol. 2022;117:1444–1453. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical